Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
In a previous study that matched populations from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN 6) and Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) cardiovascular outcome trials using the propensity score method, semaglutide reduced 3-point MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) by 26% compared to dulaglutide, although the reduction was not statistically significant (hazard ratio [HR], 0.74
Semaglutide Dosing Guide In-depth dosing protocols, clinical trial data, and pharmacokinetics
Brand-name cost is approximately $900$1,350 per month without insurance
Download your copy of GLP-1s: 2024 Trends in Drug Benefit Design Report Findings from the form on this page to learn about your peers experience navigating the GLP-1 landscape
US$ 28.06
.webp)
US$ 28.43
US$ 26.59
US$ 20.24
US$ 20.93
US$ 29.31
US$ 22.03
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
.png)
.png)